

<b>Title of meeting:</b>	Health and Wellbeing Board
<b>Date of meeting:</b>	21 <sup>st</sup> September 2022
<b>Subject:</b>	Pharmaceutical Needs Assessment 2022
<b>Report by:</b>	Matt Gummerson, Head of Strategic Intelligence and Research
<b>Wards affected:</b>	All
<b>Key decision:</b>	No
<b>Full Council decision:</b>	No

---

## **1. Purpose of report**

- 1.1 The Health and Wellbeing Board has a statutory responsibility to publish a statement of the needs for pharmaceutical services of the population in its area, referred to as a Pharmaceutical Needs Assessment (PNA). The current PNA was approved by the HWB in 2018. The statutory requirement to publish a new PNA was delayed in response to the Covid-19 pandemic. The new PNA must be approved by the HWB and published by 1<sup>st</sup> October 2022.
- 1.2 In line with the recommendations agreed by the HWB on 9<sup>th</sup> February 2022, a draft PNA was published for consultation in March 2022. The consultation closed on 6<sup>th</sup> June 2022, and the responses to the consultation are summarised in section 4.3 below. The consultation findings have not changed the conclusion of the PNA. This report seeks HWB approval to publish the statutory PNA attached as Appendix A by 1<sup>st</sup> October 2022 in line with the regulations.

## **2. Recommendations**

- 2.1 The HWB is asked to:
  1. Approve the final Pharmaceutical Needs Assessment 2022 as set out at Appendix A.

## **3. Background**

- 3.1 The PNA is a report on the local needs for pharmaceutical services. It is used to identify gaps in current services or improvements that could be made to current or future service provision. The specific content of the PNA is set out in schedule 1 of the NHS (Pharmaceutical & Local Pharmaceutical Services) Regulations 2013. It is a statutory requirement for the Health and Wellbeing Board to publish a revised

assessment within three years of its previous PNA. This requirement was delayed in 2021 by the Department of Health and Social Care in light of the pressures on the health and social care system brought about by the Covid-19 pandemic. The refreshed Portsmouth PNA must now be published on 1<sup>st</sup> October 2022.

- 3.2 The draft Portsmouth PNA 2022 which underwent consultation concludes that in Portsmouth there are 37 community pharmacies, one distance selling pharmacy and one dispensing appliance contractor. The Health and Wellbeing Board (HWB) consider the location, number, distribution and choice of pharmaceutical services serving the Portsmouth residents to meet the needs of the population. The HWB also consider that there is currently no identified need for improvements and better access to pharmaceutical services in Portsmouth.

#### **4. Reasons for recommendations**

- 4.1 PNAs are relevant when deciding if new pharmacies are needed, in response to applications by businesses, including independent owners and large pharmacy companies. Applications are contested by applicants and existing NHS contractors and can be open to legal challenge if not handled properly. They also inform commissioning decisions by local commissioning bodies.
- 4.2 The content of PNAs is set out in Schedule 1 to the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. They must include:
- A statement of the pharmaceutical services provided that are necessary to meet needs in the area;
  - A statement of the pharmaceutical services that have been identified by the HWB that are needed in the area, and are not provided (gaps in provision);
  - A statement of the other services which are provided, which are not needed, but which have secured improvements or better access to pharmaceutical services in the area;
  - A statement of the services that the HWB has identified as not being provided, but which would, if they were to be provided, secure improvements or better access to pharmaceutical services in the area;
  - A statement of other NHS services provided by a local authority, the NHS Commissioning Board (NHS England), a Clinical Commissioning Group (CCG) or an NHS Trust, which affect the needs for pharmaceutical services;
  - An explanation of how the assessment has been carried out (including how the consultation was carried out); and
  - A map of providers of pharmaceutical services.
- 4.3 There is a regulatory duty (NHS (Pharmaceutical & Local Pharmaceutical Services) Regulations 2013 No 349: Part 2: Reg 8) to have a 60-day consultation about the contents of the assessment it is making. As part of the Portsmouth PNA refresh, the consultation ran from Friday 1<sup>st</sup> April to Monday 6<sup>th</sup> June 2022. 10 responses were received: 4 representing the views of an organisation such as a Health and Wellbeing Board, Local Pharmaceutical Committee, Local Medical Committee or CCG; 2 personal views as a pharmaceutical professional working in a community

pharmacy; 1 personal view as a member of the public; and 3 others. The responses to the consultation were positive, with 100% of responses agreeing or strongly agreeing with the conclusions of the PNA.

- 4.3.1 100% of respondents also agreed or strongly agreed with the following statements:
- The purpose of the pharmaceutical needs assessment has been explained within the draft document
  - The draft PNA reflects the current provision of pharmaceutical services in your area
  - The draft PNA identifies gaps in service provision i.e. when, where and which services are available that have not been identified in the PNA
  - The draft PNA reflects the needs of your area's population
  - The draft PNA provides information to inform market entry decisions i.e. decisions on applications for new pharmacies and dispensing appliance contractor premises
  - The draft PNA provides information to inform how pharmaceutical services may be commissioned in the future
  - The draft PNA provides enough information to inform future pharmaceutical services provision and plans for pharmacies and dispensing appliance contractors.
- 4.3.2 One respondent (25% of the 4 respondents to answer this question) agreed with the statement "There are gaps in pharmaceutical services that could be provided in a community pharmacy setting in the future that have not been highlighted". However, no further information was provided as to what these gaps might be.
- 4.3.3 One specific comment about recent changes to opening hours was provided. This has been addressed through the changes set out in section 4.4 below.
- 4.4 The PNA sets out the position at a particular point in time, with the majority of the document using analysis carried out prior to the publication of the draft PNA in March 2022. There is a process for updating the PNA through supplementary statements when required in response to major changes in pharmacy provision. Some minor changes to the draft PNA have been made however between the draft and final versions.
- 4.4.1 NHSE have provided an updated list of pharmacy opening times as at 1<sup>st</sup> August 2022. This has been used to update section 6.1, and additional maps showing this information has been included as an appendix to the main report. These changes have been analysed and they do not change the PNA's assessment of accessibility to pharmacy services.
- 4.4.2 From 1<sup>st</sup> July 2022, the Hampshire and Isle of Wight Integrated Care Board assumed delegated responsibility for commissioning of pharmaceutical services in the area that were previously delegated to the CCG. This change has been reflected in the final PNA.
- 5. Integrated impact assessment**
- 5.1 An Integrated Impact Assessment has been completed.

**6. Legal implications**

- 6.1 There is a statutory duty requiring the Health and Wellbeing Board to undertake and publish this needs assessment under section 128A of the National Health Service Act 2006 and regulations made under that section, namely the National Health Service (Pharmaceutical & Local Pharmaceutical Services) Regulations 2013 ("the 2013 Regulations")
- 6.2 Regulations 3 to 9 and Schedule 1 of the 2013 Regulations set out the detailed requirements as to the content of needs assessments and the manner in which the assessment is to be made and published.

**7. Director of Finance's comments**

- 7.1 There are no direct financial implications arising from the recommendations within this report.

.....  
Signed by:

Helen Atkinson, Director of Public Health

**Appendices:**

- Appendix A - Portsmouth Pharmaceutical Needs Assessment 2022
- Appendix B - Integrated Impact Assessment

**Background list of documents: Section 100D of the Local Government Act 1972**

The following documents disclose facts or matters, which have been relied upon to a material extent by the author in preparing this report:

Title of document	Location
Draft Pharmaceutical Needs Assessment 2022	<a href="https://www.portsmouth.gov.uk/wp-content/uploads/2022/03/portsmouth-pharmaceutical-draft-needs-assessment-2022-accessible.pdf">https://www.portsmouth.gov.uk/wp-content/uploads/2022/03/portsmouth-pharmaceutical-draft-needs-assessment-2022-accessible.pdf</a>

The recommendation(s) set out above were approved/ approved as amended/ deferred/ rejected by ..... on .....

.....  
Signed by: